Your Health, We Care
On May 6, 2020, the U.S. Food and Drug Administration (FDA) approved Tabrecta (capmatinib) for the treatment of metastatic non-small cell lung cancer (mNSCLC) with MET exon 14 skipping mutation.
On February 11, 2020, Novartis announced that the U.S. Food and Drug Administration (FDA) had accept···【more】
Recommended：272026-09-01
On May 6, 2020, Novartis announced today that the U.S. Food and Drug Administration (FDA) has approv···【more】
Recommended：262026-09-01
On February 11, 2020, Novartis announced that the U.S. Food and Drug Administration (FDA) had accepted the New Drug Application (NDA) for the MET inhibitor capmatinib (INC280) and ···【more】
Article source：Lucius LaosRelease date：2026-01-09Recommended：27
On May 6, 2020, Novartis announced today that the U.S. Food and Drug Administration (FDA) has approved Tepotinib™ (Capmatinib, formerly known as INC280), an oral MET inhibitor, for···【more】
Article source：Lucius LaosRelease date：2026-01-09Recommended：26
Capmatinib inhibits the proliferation and survival of MET-dependent cancer cells by inhibiting MET phosphorylation triggered by hepatocyte growth factor binding or MET amplificatio···【more】
Article source：Lucius LaosRelease date：2024-08-07Recommended：161
Capmatinib is highly selective for c-Met targets, can effectively inhibit the proliferation and migration of c-Met-dependent tumor cells, and can effectively induce apoptosis to ac···【more】
Article source：Lucius LaosRelease date：2024-08-07Recommended：198
Capmatinib inhibits MET phosphorylation by hepatocyte growth factor binding or triggered by MET amplification, as well as MET-mediated phosphorylation of downstream signaling prote···【more】
Article source：Lucius LaosRelease date：2024-08-06Recommended：162
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
